Reference entry · Cone snail conopeptide
Ziconotide
Also known as: Prialt · ω-conotoxin MVIIA · SNX-111
- Class
- Cone snail conopeptide
- Size
- 25 amino acids
- Primary targets (literature)
- N-type voltage-gated calcium channels (Cav2.2)
- Regulatory context
- FDA-approved as Prialt (intrathecal use only). Catalog ziconotide is research material and is not a substitute for the approved formulation without full regulatory and analytical equivalence.
Overview
Ziconotide is a marine-derived conopeptide approved as an intrathecal analgesic for severe chronic pain — a rare example of a catalog-discussed peptide with full regulatory approval under defined administration constraints. RUO supply is not the approved drug product.
Mechanism in research literature
Selective Cav2.2 blockade inhibits presynaptic calcium influx and neurotransmitter release at nociceptive synapses in spinal cord pain circuits — producing potent analgesia in formal trials with a narrow therapeutic window.
Common research focus areas
- Intrathecal analgesia trial literature (Prialt)
- Cav2.2 pharmacology and conopeptide selectivity
- Neuropsychiatric adverse-effect monitoring in trials
- Conopeptide disulfide connectivity and MS identity
Full literature roundup
Read the cited research summary
A cone-snail conopeptide approved as intrathecal analgesic Prialt — and a distinct research catalog entity. Cav2.2 pharmacology, trial evidence, and identity standards.
Ziconotide research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.